📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. (2022)

First Author: Gershenson DM
Attributed to:  Precision medicine and the mutational landscape of high grade serous ovarian cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02175-9

PubMed Identifier: 35123694

Publication URI: http://europepmc.org/abstract/MED/35123694

Type: Journal Article/Review

Volume: 399

Parent Publication: Lancet (London, England)

Issue: 10324

ISSN: 0140-6736